San Diego, California and Saffron Walden, UK, 14th July 2020 / Sciad Newswire / Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.
Invivoscribe’s therapeutics division also announced today that the company has in-licensed technology involving a preclinical molecule and associated small molecules from…
Cambridge, UK, 7th July 2020: Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB). Dr. Mayr will initially join the Board of Directors as an observer, providing valuable insights into the development and manufacture of ex vivo cell therapies and in vivo reprogramming therapies and advising on the Company’s therapeutic program selections, before assuming full…
A Spanish SME, in collaboration with a local University, has been developing an advanced drug delivery system which allows to increase the therapeutic efficacy of chemotherapeutics against Non-Small Cell Lung Cancer (NSCLC). The goal of this Eurostars proposal is to obtain a full-characterized antitumoral product ready to be tested in clinical trials. They are looking for a partner to carry out the preclinical regulatory trials.
Cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer (…
Now that lockdown measures are beginning to ease and the prospect of meeting up with friends and family in a restaurant or having a drink in a pub has arrived, businesses are planning for what a return to the workplace will look like.
But as lockdown measures gradually begin to ease and we all start to look towards the future, businesses are and have been continually pondering and planning for what a return to the workplace will look like.
As financial pressures mount, one of the burning questions for many business seems to be ‘well, we’ve managed to keep people working from home successfully…
We are delighted to announce Illumina Accelerator is accepting applications for its next global funding cycle in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry. It drives value for genomics startups developing breakthrough applications in therapeutics, diagnostics, agriculture, direct to consumer, synthetic biology, and beyond. Selected genomics startups will receive access to capital, business guidance, and fully operational lab space for six months…
We continue to feel the impact of COVID-19, on a personal, organisational and national level.
For those working in supply chain management, COVID-19 has been the latest in a recent series of disruptive global challenges, including volcanic eruptions, earthquakes and war. Such global challenges undoubtedly lead to supply chain shock.
Unlike some challenges which are contained within regions, states or continents, the pandemic has sent shockwaves across the entire globe. As a result, all international supply chains have felt the effects of COVID-19.
So, how do we manage this situation?
The…
- Long-term partnership to facilitate cancer research through development of custom antibodies- Agreement to enable global access to resulting reagents and potential diagnostics
London, UK and Cambridge, UK – 07 July 2020 – Today, Cancer Research UK, the world’s largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents and tools, are pleased to announce a new partnership for the development and commercialization of novel custom antibodies to support the acceleration of cancer research.Under the terms of the partnership, Abcam will develop custom…
Reading Scientific Services Ltd (RSSL) has received the MHRA-recognised Cogent Gold Standard approval for its Responsible Person (RP) training course. The announcement follows a rigorous 18-month process, during which RSSL successfully developed and mapped all of its course material against the Gold Standard requirements.
“We are exceptionally proud to gain this prestigious accreditation, which is widely regarded as the industry benchmark and currently secured by only a few training organisations. It’s the result of dedicated efforts by our team of experienced consultants to revise, enhance…
CAMBRIDGE, UK– 6 July 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (“Pfizer”)(NYSE: PFE).Mission and Pfizer Inc. have also expanded their relationship by entering into an evaluation and option agreement for DUB target validation.Fund raisingPfizer Ventures has been an investor in Mission Therapeutics since 2013. Today it made a…
CAMBRIDGE, UK – 30 June 2020 – BioStrata, the life science marketing specialist, has appointed two new recruits further advancing the agency’s expert marketing team. Joanne Butler, a CIM qualified, creative and strategic senior marketer with 20 years of experience in B2B marketing agencies, takes on the newly created role of Client Services Director. In this role she will foster innovation and lead the team in delivering industry-leading strategic marketing campaigns for clients. Meanwhile, April Taylor joins as Marketing Communications Executive leveraging a background in biomedical…